-+ 0.00%
-+ 0.00%
-+ 0.00%
China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myeloma
Share
Listen to the news
China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myeloma
  • China’s NMPA cleared a Phase Ib/II combination trial of Heidelberg Pharma’s HDP-101 in relapsed or refractory multiple myeloma.
  • Huadong Medicine will run the study in China, covering development costs under its regional licensing deal for HDP-101.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending